Kelsey P Drasites

Ms. Kelsey P Drasites


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2021 in Metabolic Brain Disease
Verified
Journal Article
Closed access
PDF file
VZVandana Zaman
Vandana Zaman
DSDonald C. Shields
Donald C. Shields
RSRamsha Shams
Ramsha Shams
Kelsey DrasitesKelsey Drasites
Kelsey Drasites
DMDenise Matzelle
Denise Matzelle
NBNaren L. Banik
Naren L. Banik

Verified
Journal Article
Open access
PDF file
Ramsha ShamsRamsha Shams
Ramsha Shams
Kelsey DrasitesKelsey Drasites
Kelsey Drasites
VZVandana Zaman
Vandana Zaman
DMDenise Matzelle
Denise Matzelle
DSDonald C. Shields
Donald C. Shields
NBNaren L. Banik
Naren L. Banik
Spinal cord injury (SCI) affects approximately 300,000 people in the United States. Most individuals who sustain severe SCI also develop subsequent osteoporosis. However, beyond immobilization-related lack of long bone loading, multiple mechanisms of SCI-related bone density loss are incompletely understood. Recent findings suggest neuronal impairment and disability may lead to an upregulation of receptor activator of nuclear factor-κB ligand (RANKL), which promotes bone resorption. Disruption of Wnt signaling and dysregulation of RANKL may also contribute to the pathogenesis of SCI-related osteoporosis. Estrogenic effects may protect bones from resorption by decreasing the upregulation of RANKL. This review will discuss the current proposed physiological and cellular mechanisms explaining osteoporosis associated with SCI. In addition, we will discuss emerging pharmacological and physiological treatment strategies, including the promising effects of estrogen on cellular protection.

16 July 2021 in Neurochemical Research
Verified
Journal Article
Closed access
PDF file
Azizul HaqueAzizul Haque
Azizul Haque
Kelsey DrasitesKelsey Drasites
Kelsey Drasites
ACApril Cox
April Cox
MCMollie Capone
Mollie Capone
AMAli I. Myatich
Ali I. Myatich
NBNaren L. Banik
Naren L. Banik

2 December 2020 in Brain Sciences
Verified
Journal Article
Open access
PDF file
Kelsey DrasitesKelsey Drasites
Kelsey Drasites
Ramsha ShamsRamsha Shams
Ramsha Shams
VZVandana Zaman
Vandana Zaman
DMDenise Matzelle
Denise Matzelle
DSDonald C. Shields
Donald C. Shields
NBNaren L. Banik
Naren L. Banik
A spinal cord injury (SCI) may lead to loss of strength, sensation, locomotion and other body functions distal to the lesion site. Individuals with SCI also develop secondary conditions due to the lack of skeletal muscle activity. As SCI case numbers increase, recent studies have attempted to determine the best options to salvage affected musculature before it is lost. These approaches include pharmacotherapeutic options, immunosuppressants, physical activity or a combination thereof. Associated biomarkers are increasingly used to determine if these treatments aid in the protection and reconstruction of affected musculature.

24 August 2025 in Cells
Verified
Journal Article
Open access
PDF file
VZVandana Zaman
Vandana Zaman
AGAmy Gathings
Amy Gathings
Kelsey DrasitesKelsey Drasites
Kelsey Drasites
DSDonald C. Shields
Donald C. Shields
NBNaren L. Banik
Naren L. Banik
Azizul HaqueAzizul Haque
Azizul Haque
Parkinson’s disease (PD) is characterized by the progressive loss of dopaminergic neurons in the substantia nigra, and key pathways such as neuroinflammation, oxidative stress, and autophagy are believed to significantly contribute to the mechanisms of neurodegeneration. Calpain activation plays a critical role in neuroinflammation and neurodegeneration, as demonstrated by its impact on microglial activation, reactive oxygen species (ROS) production, and neuronal survival. In this study, we investigated the effects of calpain inhibition using calpeptin (CP) and calpain-2-specific inhibitors in cellular and murine models of neuroinflammation and PD. In BV2 microglial cells, LPS-induced production of pro-inflammatory cytokines (TNF-α, IL-6) and chemokines (MCP-1, IP-10) were significantly reduced by CP treatment with a concomitant decrease in ROS generation. Similarly, in VSC-4.1 motoneuron cells, calpain inhibition attenuated IFN-γ-induced ROS production and improved cell viability, demonstrating its neuroprotective effects. Moreover, in a murine MPTP model of PD, calpain inhibition reduced astrogliosis, ROCK2 expression, and levels of inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-7, and IL12p70) and chemokines (MCP-1 and IP-10) in the dorsal striatum and plasma. The specific role of calpain-2 in immune modulation was further highlighted in human microglia, SV-40 cells. With respect to immune modulation in these cells, siRNA-mediated knockdown of calpain-2, but not calpain-1, significantly reduced antigen presentation to CD4+ T cells. Thus, calpain-2 is likely involved in regulating antigen presentation and activation of inflammatory CD4+ T cells. These findings underscore the therapeutic potential of calpain-2 inhibition in mitigating neuroinflammation and neurodegeneration, particularly in PD, by targeting microglial activation, ROS production, and neuronal survival pathways.